These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 12131305

  • 1. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ.
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
    Scholz M, Jennrich R, Strum S, Brosman S, Johnson H, Lam R.
    J Urol; 2005 Jun; 173(6):1947-52. PubMed ID: 15879788
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
    Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ.
    J Clin Oncol; 2004 Mar 15; 22(6):1025-33. PubMed ID: 15020604
    [Abstract] [Full Text] [Related]

  • 6. Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer.
    Srinivas S, Krishnan AV, Colocci N, Feldman D.
    Urology; 2006 May 15; 67(5):1001-6. PubMed ID: 16698360
    [Abstract] [Full Text] [Related]

  • 7. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
    Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ.
    Clin Cancer Res; 2007 Apr 01; 13(7):2030-7. PubMed ID: 17404083
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
    Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK.
    J Urol; 2007 Jun 01; 177(6):2146-50. PubMed ID: 17509304
    [Abstract] [Full Text] [Related]

  • 9. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.
    Wilkinson S, Chodak G.
    Eur Urol; 2004 May 01; 45(5):581-4; discussion 585. PubMed ID: 15082199
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ.
    Eur Urol; 1999 May 01; 35 Suppl 1():32-6. PubMed ID: 10081701
    [Abstract] [Full Text] [Related]

  • 13. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
    Small EJ, Baron AD, Fippin L, Apodaca D.
    J Urol; 1997 Apr 01; 157(4):1204-7. PubMed ID: 9120902
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct 01; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 17. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ, Karam JA, Benaim EA.
    Urology; 2004 Apr 01; 63(4):732-6. PubMed ID: 15072890
    [Abstract] [Full Text] [Related]

  • 18. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ, Hernandez-McClain J, Henary H.
    Am J Clin Oncol; 2008 Dec 01; 31(6):532-8. PubMed ID: 19060583
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.